Key Considerations

❖How should the preclinical research community determine which preclinical models may signal treatments that would successfully make it through clinical trials? ❖Should failure of treatment effectiveness in preclinical behavioral tests related to ethanol consumption stop a drug from moving to preclinical trials? ❖Considering the similar underlying pathways of food, drug, and other natural reinforcements, when do non-specific drug effects become a red flag? ❖How do we effectively consider aspects of personalized medicine, such as genetic contributions?

Suggestions

❖Test drugs that have and have not passed FDA clinical trials for alcohol use disorders in a large range of behavioral tests in an attempt to find critical aspects that may suggest success. ❖Maintain open source preclinical, human laboratory, and clinical trial databases with positive and negative results that can easily be cross-referenced. ❖Consider combined subthreshold doses of efficacious drugs that display anhedonic or amotivational effects. ❖Cross-reference human findings to identify genetic targets which can be manipulated in preclinical models.